Overview

SPG Block for Acute Pediatric Migraine

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.
Phase:
Phase 3
Details
Lead Sponsor:
Newark Beth Israel Medical Center
Treatments:
Lidocaine
Prochlorperazine